{"id":37505,"date":"2023-04-11T12:10:58","date_gmt":"2023-04-11T10:10:58","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=37505"},"modified":"2023-04-18T09:42:40","modified_gmt":"2023-04-18T07:42:40","slug":"danish-biotech-weekly-2","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/","title":{"rendered":"Danish Biotech Weekly"},"content":{"rendered":"\n

In the past week<\/strong> several companies announced updates to their clinical trial updates that usually acts as price trigger events for the share price. Furthermore, Synact Pharma announced a new CEO, while Genmab completed its share buy-back program<\/strong>.<\/p>\n\n\n\n

10 of the 20 listed, Danish biotech companies have published news the past week. 10 of the companies had a positive development in their share price for the week and 6 companies have had a positive share price performance year to date.<\/strong><\/p>\n\n\n\n

\n
Registration for the Danish Biotech Weekly newsletter<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Company news the past week<\/strong><\/p>\n\n\n\n

Ascendis Pharma<\/strong><\/p>\n\n\n\n

Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH\u2122 in Hypoparathyroidism (LINK)<\/a><\/p>\n\n\n\n

Ascendis Pharma\u2019s Initial Dose Escalation Results from the Ongoing Phase 1\/2 Trial of TransCon\u2122 IL-2 \u03b2\/\u03b3 Accepted for Online Publication at ASCO 2023 (LINK)<\/a><\/p>\n\n\n\n

Oppenheimer Downgrades Ascendis Pharma to Market Perform<\/p>\n\n\n\n

Biosergen<\/strong><\/a><\/p>\n\n\n\n

Analyseupdate in Swedish- Minskad risk efter positiva fas 1-studier – Mangold Insight Analys (LINK)<\/a><\/p>\n\n\n\n

Cessatech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

CS Medica<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Curasight<\/strong><\/a><\/strong><\/p>\n\n\n\n

Notice of Annual General Meeting 2023 (LINK<\/a>)<\/p>\n\n\n\n

Evaxion Biotech<\/strong><\/p>\n\n\n\n

BioStock: Evaxion to sharpen focus and launch new platform (LINK)<\/a><\/p>\n\n\n\n

Lake Street Capital Lowers Evaxion Biotech Price Target to $7.00<\/p>\n\n\n\n

Expres2ion<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Fluoguide<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Genmab<\/strong><\/p>\n\n\n\n

Completion of share buy-back program (LINK)<\/a><\/p>\n\n\n\n

1. Transactions With Shares and Linked Securities in Genmab A\/S Made by Managerial Employees and Their Closely Associated Persons (LINK)<\/a><\/p>\n\n\n\n

2. Transactions With Shares and Linked Securities in Genmab A\/S Made by Managerial Employees and Their Closely Associated Persons (LINK)<\/a><\/p>\n\n\n\n

Gubra<\/strong><\/p>\n\n\n\n

Completion of the offering and registration of capital increase in Gubra A\/S (LINK)<\/a><\/p>\n\n\n\n

Initiator Pharma<\/strong><\/p>\n\n\n\n

Initiator Pharma completes dosing in Phase 2a trial with IP2018 (LINK)<\/a><\/p>\n\n\n\n

IO Biotech<\/strong><\/p>\n\n\n\n

No news past the week<\/em><\/p>\n\n\n\n

Pila Pharma<\/strong><\/p>\n\n\n\n

CEO Dorte X. Gram announces further increase of its holding in Pila Pharma AB<\/p>\n\n\n\n

Saniona<\/strong><\/p>\n\n\n\n

BioStock: Saniona\u00b4s obesity drug one step closer to approval (LINK)<\/a><\/p>\n\n\n\n

BioStock: Saniona sees potential for value-creating milestones (LINK)<\/a><\/p>\n\n\n\n

Scandion Oncology<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

SynAct Pharma<\/strong><\/p>\n\n\n\n

SynAct Pharma appoints Torbj\u00f8rn Bjerke as new CEO (LINK)<\/a><\/p>\n\n\n\n

ViroGates<\/strong><\/p>\n\n\n\n

ViroGates announces preliminary results for Q1, 2023: Quarterly revenue affected by a slower-than-expected conversion of COVID-19 hospitals into use in triage in the emergency department (LINK)<\/a><\/p>\n\n\n\n

Zealand Pharma<\/strong><\/p>\n\n\n\n

Zealand Pharma A\/S publishes a listing prospectus regarding admission to trading and official listing of 6,578,948 new shares on Nasdaq Copenhagen (LINK)<\/a><\/p>\n\n\n\n

Zealand Pharma completes registration of capital increase (LINK)<\/a><\/p>\n\n\n\n

Y-mAbs Therapeutics<\/strong><\/p>\n\n\n\n

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA (LINK)<\/a><\/p>\n\n\n\n

2cureX<\/strong><\/p>\n\n\n\n

2CUREX STRENGTHENS ITS INDITREAT\u00ae AUTOMATION PROJECT WITH A PRESTIGIOUS GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH (LINK)<\/a><\/p>\n\n\n\n

SHARE PRICE DEVELOPMENTS<\/strong><\/p>\n\n\n\n

Pila Pharma AB<\/strong> was the best performing Danish biotech company last week with a 27% increase after the CEO bought shares. At the opposite end of the spectrum was Ascendis Pharma A\/S<\/strong> fell 32% after releasing dose results from the ongoing phase 1\/2 trial of TransCon as well as a regulatory review. Since the start of the year, most of the companies have been under pressure, while especially Saniona AB, Zealand Pharma A\/S <\/strong>and Fluoguide AB<\/strong> have performed well. Saniona has made a strong comeback after several years of downturns. This follows a possible approval for the company’s weight loss lead-candidate in Mexcio, which could generate royalties for Saniona.<\/p>\n\n\n\n

Read more about Fluoguide:<\/strong><\/mark> The unique cancer treatment of the future – Today’s investment<\/a><\/p>\n\n\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

In the past week several companies announced updates to their clinical trial updates that usually acts as price trigger events for the share price. Furthermore, Synact Pharma announced a new CEO, while Genmab completed its share buy-back program. 10 of the 20 listed, Danish biotech companies have published news the past week. 10 of the […]<\/p>\n","protected":false},"author":11,"featured_media":37397,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[221],"tags":[],"class_list":["post-37505","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cs-medica-en"],"acf":[],"yoast_head":"\nDanish Biotech Weekly | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Danish Biotech Weekly | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"In the past week several companies announced updates to their clinical trial updates that usually acts as price trigger events for the share price. Furthermore, Synact Pharma announced a new CEO, while Genmab completed its share buy-back program. 10 of the 20 listed, Danish biotech companies have published news the past week. 10 of the […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T10:10:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-18T07:42:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1015\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Danish Biotech Weekly\",\"datePublished\":\"2023-04-11T10:10:58+00:00\",\"dateModified\":\"2023-04-18T07:42:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/\"},\"wordCount\":564,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"articleSection\":[\"CS Medica\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/\",\"name\":\"Danish Biotech Weekly | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"datePublished\":\"2023-04-11T10:10:58+00:00\",\"dateModified\":\"2023-04-18T07:42:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"width\":1015,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CS Medica\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/cs-medica-en\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Danish Biotech Weekly\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Danish Biotech Weekly | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/","og_locale":"en_US","og_type":"article","og_title":"Danish Biotech Weekly | Kapital Partner A\/S","og_description":"In the past week several companies announced updates to their clinical trial updates that usually acts as price trigger events for the share price. Furthermore, Synact Pharma announced a new CEO, while Genmab completed its share buy-back program. 10 of the 20 listed, Danish biotech companies have published news the past week. 10 of the […]","og_url":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2023-04-11T10:10:58+00:00","article_modified_time":"2023-04-18T07:42:40+00:00","og_image":[{"width":1015,"height":533,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","type":"image\/png"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Danish Biotech Weekly","datePublished":"2023-04-11T10:10:58+00:00","dateModified":"2023-04-18T07:42:40+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/"},"wordCount":564,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","articleSection":["CS Medica"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/","url":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/","name":"Danish Biotech Weekly | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","datePublished":"2023-04-11T10:10:58+00:00","dateModified":"2023-04-18T07:42:40+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","width":1015,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"CS Medica","item":"https:\/\/kapitalpartner.dk\/en\/category\/cs-medica-en\/"},{"@type":"ListItem","position":3,"name":"Danish Biotech Weekly"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/37505"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=37505"}],"version-history":[{"count":2,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/37505\/revisions"}],"predecessor-version":[{"id":37507,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/37505\/revisions\/37507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/37397"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=37505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=37505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=37505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}